• 1. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020
• 2. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 3. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 4. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509
• 5. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Trifluoromethylbenzenes

Recent Advances in the Study of 3'-Trifluoromethylcyclopentanecarboxanilide (CAS: 13691-84-4)

3'-Trifluoromethylcyclopentanecarboxanilide (CAS: 13691-84-4) is a compound of significant interest in the field of chemical biology and pharmaceutical research. Recent studies have focused on its potential applications in drug development, particularly due to its unique structural properties and biological activity. This research brief aims to summarize the latest findings related to this compound, including its synthesis, mechanism of action, and therapeutic potential.

One of the key areas of investigation has been the synthesis and optimization of 3'-Trifluoromethylcyclopentanecarboxanilide. Researchers have developed novel synthetic routes to improve yield and purity, which are critical for scaling up production for preclinical and clinical studies. Recent publications highlight the use of advanced catalytic methods and green chemistry principles to achieve these goals, reducing environmental impact while maintaining high efficiency.

In terms of biological activity, 3'-Trifluoromethylcyclopentanecarboxanilide has shown promising results in targeting specific enzymes and receptors involved in inflammatory and oncogenic pathways. For instance, a 2023 study demonstrated its efficacy as a selective inhibitor of cyclooxygenase-2 (COX-2), a key enzyme in the inflammatory response. This finding suggests potential applications in the treatment of chronic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.

Another significant development is the exploration of 3'-Trifluoromethylcyclopentanecarboxanilide as a potential anticancer agent. Preclinical studies have revealed its ability to induce apoptosis in certain cancer cell lines, particularly those resistant to conventional chemotherapy. The compound's mechanism of action appears to involve the modulation of apoptotic signaling pathways, making it a candidate for combination therapies with existing anticancer drugs.

Despite these promising findings, challenges remain in the development of 3'-Trifluoromethylcyclopentanecarboxanilide as a therapeutic agent. Issues such as bioavailability, metabolic stability, and potential off-target effects need to be addressed through further research. Recent efforts have focused on structural modifications to enhance pharmacokinetic properties while retaining biological activity.

In conclusion, 3'-Trifluoromethylcyclopentanecarboxanilide (CAS: 13691-84-4) represents a compound with substantial potential in drug discovery and development. Ongoing research is expected to provide deeper insights into its therapeutic applications and optimize its properties for clinical use. The integration of computational modeling, high-throughput screening, and advanced synthetic techniques will likely play a pivotal role in advancing this compound toward clinical trials.

• 2300-87-0(3'-Trifluoromethyl-2,2-dimethylvaleranilide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)